21-基因复发评分芯片对早期乳腺癌患者预后作用的研究进展被引量：1

Prognostic role of a 21- gene recurrence score assay in patients with early breast cancer

导出

摘要 21-基因复发评分芯片是一种判断乳腺癌预后的工具，通过检测21种基因并计算复发分数（Rs），从而将患者分为低、中、高危组来判断预后。与现有的几种判断预后工具相比较，21-基因芯片有着更大的优势，与传统预后因素联合应用可明显提高预测患者预后的准确性。 21-Gene recurrence score assay is a tool of judging the prognosis of breast cancer. Through detecting the 21kind of genes and calculating the recurrence score （RS） ,the patients can be divided into three groups： low, intermediate, and high risk groups. Comparing with other tools, 21-gene assay is more accurate, especially used with other traditional prognostic factors.

作者张丽(综述) 佟仲生(审校)

机构地区天津医科大学附属肿瘤医院乳腺肿瘤内科

出处《国际肿瘤学杂志》 CAS 2009年第1期27-30,共4页 Journal of International Oncology

关键词 21-基因复发评分芯片乳腺肿瘤预后 21-gene recurrence score assay Breast neoplasms Prognosis

分类号 R512.62 [医药卫生—内科学] R512.6 [医药卫生—内科学]

引文网络
相关文献

参考文献22

1Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oneologist, 2007, 12(6) :631-635.
2Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol, 2006, 24(23) :3726-3734.
3Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation, lnt J Cancer, 1983, 31 (1) :13-20.
4Dowsett M, Smith IE, Ebbs SR, et al . Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 2007, 99 (2) : 167-170.
5Nassar A, Sexton D, Cotsonis G, et al. Survivin expression in breast carcinoma: correlation with apoptosis and prognosis. Appl Immunohistochem Mol Morphol, 2008, 16(3):221-226.
6Dawood S, Broglio K, Gong Y, et al. Prognostic significance of HER- 2 status in women with inflammatory breast cancer. Cancer, 2008, 112(9) : 1905-1911.
7Papadopoulou E, Tripsianis G, Anagnostopoulos K, et al. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma, 2008, 55(2) : 113-121.
8Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst, 2004, 96 ( 3 ) : 218 - 228.
9Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol, 2008, 26(22) :3727-3734.
10Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol, 2004, 164(1) :35-42.